Compare HubSpot Inc (HUBS) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HubSpot Inc vs Novavax Inc — how do they compare? HubSpot Inc trades at $209.82 (market cap $11.00B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: HubSpot Inc is far larger — about 8.4× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals.
| HUBS | NVAX | |
|---|---|---|
Market Cap | $11.00B | $1.31B |
Sector | Technology | Health |
52-Week High | $522.97 | $11.19 |
52-Week Low | $170.39 | $6.22 |
Enterprise Value | $9.89B | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HubSpot (HUBS) trades at $210.12, down 2.68% amid a bearish technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates with $3.26 versus $3.02 expected, but lowered its 2026 customer-growth forecast, causing investor concern. Revenue growth remains robust at 20% year-over-year, while profitability metrics show improvement, with net income margin rising to 4.26% in 2025 from negative figures in prior years.
The outlook is mixed: analyst consensus is bullish with a $233.93 price target, but near-term risks include execution challenges in AI adoption and a securities fraud investigation. Long-term growth depends on successful AI product integration and customer acquisition recovery, though competitive and regulatory pressures persist.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
